Stakeholders in the life sciences industry are witnessing an increasing number of initiatives in the UK and across Europe to facilitate collective legal actions. There are a growing number of private sector entrants to the collective actions and third-party funding marketplace. The impact may increase the litigation risk in Europe, although it is important that this risk is not overstated. This article surveys key developments in collective actions and third-party funding at a European level and in a number of key European jurisdictions. It also discusses specific risks for the life sciences industry.